StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BIOG.L$1304.00-0.30%
Fair $1304.00+0.0%

BIOG.L

Biotech Growth Ord

Unknown / UnknownLSE

$1304.00

-4.00 (-0.30%)

Fairly Valued+0.0%Fair Value $1304.00Fund rank 22/100 · Data gapFallback financials|
SA 18/F
F-Score: 1/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 15%

FCF escenarios

weak_data · normalized FCF $-5.1M · quality 29.7/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

18/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. ROE is -37.4%, below the 5% threshold
Thesis & Journal · BIOG.LLocal privado en este navegador · Biotech Growth Ord
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$253M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-37.4%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$1304
$702$1374

TradingView lightweight chart

BIOG.L price, volumen y niveles de valoración

Último $1,312Periodo +1143.6%
Fair value: $1,304

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

6.5%

FCF / Net income

0.06x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $-78.8M · net income $-82.7M · FCF $-5.1M

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

104.9%+8.4% pts

FCF margin

6.5%+0.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$-78.8M$-78.8M$78.0M$-37.7M$-209.7M
Net Income$-82.7M$-82.7M$74.6M$-41.3M$-202.4M
EPS-2.62-2.622.07-1.02-4.88
Net Margin104.9%104.9%95.6%109.7%96.5%
Balance Sheet
Debt/Equity——0.130.060.08
Cash Flow
Free Cash Flow$-5.1M$-5.1M$-4.2M$-5.9M$-12.1M
Returns
ROE-37.4%-37.4%20.6%-12.5%-51.3%
Valuation
P/E——466.18——
P/B185.77185.7796.2692.4698.82
Growth & Yield
Revenue Growth-201.0%-201.0%307.1%82.0%—
EPS Growth-226.7%-226.7%302.0%79.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +81.2%

Total return

+81.2%

Start / end P/E

n/dx → n/dx

EPS bridge

2.07 → -2.62

Residual

+81.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+81.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.